| Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial K Fox, I Ford, PG Steg, M Tendera, R Ferrari, H Grancelli, B Freedman, ... The Lancet, 2008 | 1463 | 2008 |
| Cholesterol lowering in intermediate-risk persons without cardiovascular disease New England Journal of Medicine 374 (21), 2021-2031, 2016 | 1003 | 2016 |
| Blood-pressure lowering in intermediate-risk persons without cardiovascular disease New England Journal of Medicine 374 (21), 2009-2020, 2016 | 786 | 2016 |
| Ivabradine in stable coronary artery disease without clinical heart failure FR Fox K, Ford I, Steg PG, Tardif JC, Tendera M, S Investigators. N Engl J Med. 371 (12), 1091-1099, 2014 | 618* | 2014 |
| Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. GHF Investigators. N Engl J Med 384 (2), 105-116, 2021 | 528* | 2021 |
| Blood-pressure and cholesterol lowering in persons without cardiovascular disease New England Journal of Medicine 374 (21), 2032-2043, 2016 | 477 | 2016 |
| Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF SD Pokorney, JP Piccini, SR Stevens, MR Patel, KS Pieper, JL Halperin, ... Journal of the American Heart Association, 2015 | 154 | 2015 |
| Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF HN Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Legg ... JACC Heart Fail. 8 (4), 329-340, 2020 | 140* | 2020 |
| Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral … FKA Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C ... Circulation 135 (4), 323-333, 2017 | 117 | 2017 |
| Targeting the prostacyclin pathway with selexipag in patients with pulmonary arterial hypertension receiving double combination therapy: insights from the randomized control … et al. Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA Am J Cardiovasc Drugs, 37-47, 2018 | 111 | 2018 |
| The BEAUTIFUL study: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - Baseline characteristics of the … K Fox, R Ferrari, I Ford, PG Steg, M Tendera, H Cohen Arazi, DR Nul, ... Cardiology (Switzerland), 2008 | 89* | 2008 |
| Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF J Am Coll Cardiol 78 (2), 97-108, 2021 | 84 | 2021 |
| Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial TJR Felker GM, Solomon SD, Claggett B, Diaz R, McMurray JJV, Metra M, Anand ... JAMA Cardiol 7 (1), 26-34, 2022 | 72 | 2022 |
| Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study Neurology 92 (13), e1435-e1446, 2019 | 68 | 2019 |
| Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease … FRAHJO Fox K, Ford I, Steg PG, Tardif JC, Tendera M, 166(4): 654-661 Am Heart J. 166 (4), 654-661, 2013 | 46 | 2013 |
| Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis GCM Gibson WJ, Nafee T, Travis R, Yee M, Kerneis M, Ohman M J Thromb Thrombolysis 49 (1), 1-9, 2020 | 43 | 2020 |
| Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the … CM Kerneis M, Gibson CM, Chi G, Mehran R, AlKhalfan F, Talib U, Pahlavani S ... JACC Cardiovasc Interv. 11 (7), 626-634, 2018 | 28 | 2018 |
| Блокада ренин-ангиотензин-альдостероновой системы как краеугольный камень лечения хронической сердечной недостаточности ГВ Дзяк, ЛИ Васильева Серцева недостатність 1, 18-30, 2009 | 24 | 2009 |
| Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI … GCM Chi G, Kerneis M, Kalayci A, Liu Y, Mehran R, Bode C, Halperin JL ... Am Heart J. 203, 17-24, 2018 | 19 | 2018 |
| Артериальная гипертензия. Принципы и тактика лечения ГВ Дзяк, ЛИ Васильева, АА Ханюков Днепропетровск, 2000 | 15 | 2000 |
Дзяк Георгій Вікторович | Georgy DzyakДніпровський державний медичний університет, доктор мед. наук, професорПодтвержден адрес электронной почты в домене dma.dp.ua
